The Following is IACP’s Response to the Washington Post Article – A Message from David Miller, at IACP
I wanted to make sure you were aware that the Washington Post article which appeared on Friday alleging that IACP is now supporting FDA oversight of compounding pharmacy is neither accurate nor reflective of the complete story. In fact, IACP and our PR firm gave the reporter very specific written statements were given a spin by the journalist.
The following is the exact language we gave to the reporter:
IACP is supportive of a discussion about the creation of a category of non-traditional manufacturing. A formal position has not yet been taken by the IACP or, to our knowledge, by any other pharmacy organization. This is a concept that we believe needs to be reviewed and discussed in the public arena.
For this group of non-traditional manufacturers, if they are manufacturers, we would expect that the FDA would regulate them. The FDA would have to determine if the same criteria would be applied to this category as is applied to traditional manufacturers. Any compounding pharmacy – not a manufacturer, traditional or non-traditional – should continue to be regulated and overseen by state boards of pharmacy.
In short, IACP supports a policy conversation about regulating manufacturing. We have not endorsed or supported a specific program, design, concept or anything else. Strictly a discussion. That is consistent with IACP’s statements to Congress and state regulatory authorities.
I’d sure appreciate your help in making sure that compounding pharmacists have the whole story.
David G. Miller, R.Ph.